Otsuki Toshifumi
- kawaokashinpei3
- 5 日前
- 読了時間: 1分
Selected journal : Cell metabolism
Gut microbiota and metabolic control of immune checkpoint blockade in cancer
What is the main question of the paper?
What are the exact mechanisms by which the gut microbiota and their metabolites control the efficacy of immune checkpoint blockade (ICB) in cancer therapy?
How did the anthor address the question?
■Step1
Clinical Correlation: Focused heavily on the detrimental impact of perioperative antibiotic use, demonstrating that the resulting disruption of gut microbial diversity significantly shortens patient survival during immunotherapy.
■Step2
Surgical Evidence: Murine models showing that surgical resection of the mesenteric lymph nodes reduces immunotherapy efficacy, proving that microbial translocation to lymph nodes is required to effect anti-tumor immunity.
■Step3
Metabolic Pathways: Explained how dietary factors and host factors are converted by gut bacteria into systemic metabolites that directly enhance the cytotoxicity of tumor-infiltrating CD8 T-cells.
What is the strength of the paper?
By connecting complex microbiome data to surgical oncology, this paper highlights that routine clinical factors—including perioperative antibiotics, diet, and lymph node preservation—directly impact the success of immunotherapy.
Comment
The paper clearly shows how the gut microbiota and its metabolites influence cancer immunotherapy. The unique strength of this paper lies in its innovative approach of using surgical models, such as lymph node resection, to visually prove microbial translocation. By linking complex microbiome data directly to routine clinical decisions, this study provides highly practical insights for improving treatment outcomes.
Comment by Du Yilin
